Search - tctmd.com

Displaying 1 - 20 of 29

Sort: Relevancy | Date

News Daily News

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

Michael O'Riordan

March 13, 2025

News Conference News ISET 2024

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

Caitlin E. Cox

January 24, 2024

News Daily News

Top Endovascular News of 2023

L.A. McKeown

December 28, 2023

News Conference News

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

L.A. McKeown

November 18, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

News Conference News VIVA 2020

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

L.A. McKeown

November 27, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Daily News

Recovered Paclitaxel PAD Data Shift the Mortality Picture

L.A. McKeown

May 14, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

L.A. McKeown

December 12, 2019

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

L.A. McKeown

February 19, 2019

Advertisement

Take Heed of Sex Differences in Peripheral Vascular Disease: AHA

How to Reconcile BEST-CLI and BASIL-2? A ‘Patient-First’ Strategy

Top Endovascular News of 2023

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

As ‘Paclitaxelgate’ Loses Steam, Experts Mull Lasting Impact for Future Trials, Practice

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

Recovered Paclitaxel PAD Data Shift the Mortality Picture

FDA’s First Take on New Paclitaxel Concerns in CLI

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Mortality Data ‘Inadvertently Omitted’ From IN.PACT Analysis of Paclitaxel-Coated Balloons

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content